Read by QxMD icon Read

Current Cancer Drug Targets

Peng Liu, Hailin Tang, Jiali Wu, Xingsheng Qiu, Yanan Kong, Lijuan Zhang, Xinhua Xie, Xiangsheng Xiao
Long non-coding RNAs play crucial roles in various biological activities and diseases. The role of long intergenic non-coding RNA01638 (linc01638) in breast cancer, especially in HER2-positive breast cancer,remains largely unknown. In this study, linc01638 was found to be remarkably overexpressed in HER2-positive breast cancer cells and tissues. Suppression of linc01638 enhanced cell apoptosis, as well as inhibited the growth and invasiveness of HER2-positive breast cancer cells in vitro and tumor progression and metastasis in vivo...
July 9, 2018: Current Cancer Drug Targets
Zhou Jiang, Jiqing Ye, Jingyi Yang, Jian Wang, Lee Jia, Rodney Jy Hoc
Objective:To improve solubility and to reduce aggregation, ZnPcC4 was conjugated to a third-generation polyamidoamine dendrimer with amino end group (G3-PAMAM-NH2), which acts as a novel photodynamic therapy (PDT) drug carrier system. Method:The phthalocyanines were synthesized by construction reaction. The nanodrug was obtained from the conjugation of ZnPcC4 to G3-PAMAM-NH2, using EDC and NHS as coupling agents. The ZnPcC4@G3-PAMAM-NH2 conjugation was characterized by UV-Vis and MS. The 1O2 quantum yield of ZnPcC4@G3-PAMAM-NH2 in water was measured by the chemiluminescence method...
July 6, 2018: Current Cancer Drug Targets
Muhammad Furqan Akhtar, Ammara Saleem, Alamgeer Yuchi, Mohammad Saleem
The widespread emergence of cancer and development of resistance to chemotherapeutic agents is increasing the interest of scientists in the use of ethnomedicinal preparations and isolated phytochemicals in the treatment and prevention of disease. Medicinal plants are used in Pakistan for prehistoric times. The present review was designed to identify anticancer plants of ethnomedicinal significance and to summarize the anticancer activities carried out on these medicinal plants to establish the pharmacological and phytochemical basis for their use...
July 6, 2018: Current Cancer Drug Targets
Arkene Levy, Khalid Alhazzani, Priya Dondapati, Ali Alaseem, Khadijah Cheema, Keerthi Thallapureddy, Paramajot Kaur, Saad Alobid, Appu Rathinavelu
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase, which is an essential player in regulating cell migration, invasion, adhesion, proliferation, and survival. Its overexpression and activation have been identified in sixty-eight percent of epithelial ovarian cancer patients and this is significantly associated with higher tumor stage, metastasis, and shorter overall survival of these patients. Most recently, a new role has emerged for FAK in promoting resistance to taxane and platinum based therapy in ovarian and other cancers...
July 6, 2018: Current Cancer Drug Targets
Karthikeyan Subbarayan, Barbara Seliger
BACKGROUND: The small leucine-rich proteoglycans (SLRPs) biglycan (BGN) and decorin (DCN) linked with sulfated glycosaminoglycan (GAG) chains exhibit oncogenic or tumor suppressive potentials depending on the cellular context and association with GAGs. OBJECTIVE: We hypothesized that structural alterations and expression levels of BGN, DCN and their associated chondroitin sulfate (CS) polymerizing enzymes, dermatan sulfate (DS) epimerases and various sulfatases might be correlated with the tumor (sub)type and patients' survival...
July 6, 2018: Current Cancer Drug Targets
Junsong Chen, Na Niu, Jing Zhang, Lisha Qi, Weiwei Shen, Krishna Vanaja Donkena, Zhenqing Feng, Jinsong Liu
Polyploidy is associated with increased cell size and commonly found in a subset of adult organs and blastomere stage of human embryo. The polyploidy is formed through endoreplication or cell fusion to support specific need of development including earliest embryogenesis. Recent data demonstrated that polyploid giant cancer cells (PGCCs) may have acquired an activated early embryonic-like program in response to oncogenic and therapeutic stress to generate reprogrammed cancer cells for drug resistance and metastasis...
July 3, 2018: Current Cancer Drug Targets
Yanping Cao, Zhihao Wei, Mengmeng Li, Haiyan Wang, Li Yin, Dongxiao Chen, Yanfei Wang, Yongchao Chen, Qi Yuan, Xiaohui Pu, Lanlan Zong, Shaofeng Duan
BACKGROUND: Improving poorly soluble drugs into druggability was a major problem faced by pharmaceutists. Nanosuspension can improve the druggability of insoluble drugs by improving the solubility, chemical stability and reducing the use of additives, which provided a new approach for the development and application of the insoluble drugs formulation. Paclitaxel (PTX) is a well-known BCS class IV drug with poor solubility and permeability. Also, many studies have proved that paclitaxel is a substrate of the membrane-bound drug efflux pump P-glycoprotein (P-gp), therefore it often shows limited efficacy against the resistant tumors and oral absorption or uptake...
June 29, 2018: Current Cancer Drug Targets
Xiaodong Xie, Yingying Zhang, Fengqiao Li, Tingting Lv, Ziying Li, Haijun Chen, Lee Jia, Yu Gao
BACKGROUND: Effective cancer therapy is still a great challenge for modern medical research due to the complex underlying mechanisms of tumorigenesis and tumor metastasis, and the limitations commonly associated with currently used cancer therapeutic options. Nanotechnology has been implemented in cancer therapeutics with immense potential for improving cancer treatment. OBJECTIVES: Through information about the recent advances regarding cancer hallmarks, we could comprehensively understand the pharmacological effects and explore the mechanisms of the interaction between the nanomaterials, which could provide opportunities to develop mechanism-based nanomedicine to treat human cancers through...
June 28, 2018: Current Cancer Drug Targets
Hamidreza Maroof, Soussan Irani, Armin Ariana, Jelena Vider, Vinod Gopalan, Alfred King-Yin Lam
BACKGROUND: The clinical pathological features as well as the cellular mechanisms of miR-195 have not been investigated in thyroid carcinoma. OBJECTIVE: The aim of this study is to identify the interactions of vascular endothelial growth factor (VEGF), p53 and miR-195 in thyroid carcinoma. The clinical and pathological features of miR-195 were also investigated. METHOD: The expression levels of miR-195 were identified in 123 primary thyroid carcinomas, 40 lymph nodes with metastatic papillary thyroid carcinomas and seven non-neoplastic thyroid tissues (controls) as well as two thyroid carcinoma cell lines, B-CPAP (from metastasizing human papillary thyroid carcinoma) and MB-1 (from anaplastic thyroid carcinoma), by the real-time polymerase chain reaction...
June 28, 2018: Current Cancer Drug Targets
Ishita Tandon, Nilesh Kumar Sharma
Tumor heterogeneity within various cancer types including breast carcinoma is pivotal in the manifestations of tumor hallmarks. Tumor heterogeneity is seen as a common landscape where intra-tumoral components including cellular and non-cellular factors create interface with outside environment that lead to the unique identity of a specific cancer type. Among various contributors to tumor heterogeneity, cellular heterogeneity immensely plays a role in drug resistance and relapse of cancer. Within cellular heterogeneity of tumor, tumor-associated macrophages (TAMs) are pro-tumor type of immune cells that promote growth, metastasis and drug resistance in breast carcinoma and other cancer types...
June 27, 2018: Current Cancer Drug Targets
Guillaume Poiroux, Annick Barre, Pierre Rouge, Herve Benoist
The use of photodynamic therapy in cancer still remains limited, partly because of the lack of photosensitizer (PS) specificity for the cancerous tissues. Various molecular tools are available to increase PS efficiency by targeting the cancer cell molecular alterations. The most strategies use the protein-protein interactions, e.g. monoclonal antibodies directed toward tumor antigens, such as HER2 or EGFR. An alternative could be the targeting of the tumor glycosylation aberrations, e.g. T/Tn antigens that are truncated O-glycans over-expressed in numerous tumors...
June 27, 2018: Current Cancer Drug Targets
Peng Liu, Yanfang Wu, Ziwen Lu, Dongsheng Shang, Zhicong Zhao, Yanting Shen, Yafei Zhang, Feifei Zhu, Hanqing Liu, Zhigang Tu
BACKGROUND: Recently, the chemotherapeutic drug-induced cellular senescence is considered per se a promising anti-cancer approach. This drug-induced senescence, which shows both similar, and different hallmarks from replicative senescence and oncogene-induced senescence, was regarded as a key determinant of tumor response to chemotherapy in vitro and in vivo. To date, plenty of effective chemotherapeutic drugs that evoke senescence in cancer cells have been reported. The targets of these drugs differ substantially from each other, as well as from DNA damage response, telomerase activity inhibition through senescence-related CDK, p53 and Rb signaling pathways...
May 29, 2018: Current Cancer Drug Targets
Xiang Zhang, Wei Zhang, Xing-Gang Mao, Wei-Dong Cao, Hai-Ning Zhen, Shi-Jie Hu
Malignant high grade glioma (HGG) is the most common and extremely fatal type of primary intracranial tumor. These tumors recurred within 2 to 3 cm of the primary region of tumor resection in the majority of cases. Furthermore, the blood-brain barrier significantly limited the access of many systemically administered chemotherapeutics to the tumor, pointing towards a stringent need for new therapeutic patterns. Therefore, targeting therapy using local drug delivery for HGG becomes a priority for the development of novel therapeutic strategies...
May 29, 2018: Current Cancer Drug Targets
Nazrul Islam, Derek Richard
Local delivery of drug to the target organ via inhalation offers enormous benefits in the management of many diseases. Lung cancer is the most common of all cancers and it is the leading cause of death worldwide. Currently available treatment systems (intravenous or oral drug delivery) are not efficient in accumulating the delivered drug into the target tumor cells and are usually associated with various systemic and dose-related adverse effects. The pulmonary drug delivery technology would enable preferential accumulation of drug within the cancer cell and thus be superior to intravenous and oral delivery in reducing cancer cell proliferation and minimising the systemic adverse effects...
May 24, 2018: Current Cancer Drug Targets
Andreia Alves, Ana Catarina Mamede, Marco Alves, Pedro F Oliveira, Sandra Moreira Rocha, Filomena Botelho, Claudio Jorge Maia
Hepatocellular carcinoma (HCC) is the most frequently detected primary malignant liver tumor, representing a worldwide public health problem due to its high morbidity and mortality rates. The HCC is commonly detected in advanced stage, precluding the use of treatments with curative intent. For this reason, it is crucial to find effective therapies for HCC. Cancer cells have a high dependence of glycolysis for ATP production, especially under hypoxic environment. Such dependence provides a reliable possible strategy to specifically target cancer cells based on the inhibition of glycolysis...
April 30, 2018: Current Cancer Drug Targets
Mengting Ou, Shun Li, Liling Tang
PRDM14 belongs to PR domain-containing (PRDM) family. Although a precise understanding is focused on the function of PRDM14 maintains stemness and pluripotency in embryonic stem cells via epigenetic mechanisms, there are growing experimental evidences have been linked PRDM14 to human cancers. In adults, PRDM14 is low expression in human tissues. Aberrant PRDM14 expression is connected with various malignant histological types and solid cancers, where PRDM14 can act as a driver of oncogenic processes. Overexpression of RPDM14 enhanced cancer cells growth and reduced cancer cells sensitive to chemotherapeutic agents...
April 30, 2018: Current Cancer Drug Targets
Gracia Montag, Helga Stopper, Quoc Anh Ngo, Henning Hintzsche
Vinca alkaloids are important cancer drugs belonging to the class of antimitotic agents. The most commonly used substances are vinblastine and vincristine, other compounds are vinorelbine and vinflunine. All of them are very effective drugs but their use is limited by severe side-effects including neurotoxicity and bone marrow depression. Therefore, it is very important to develop novel vinca alkaloids with similar efficacy but lower toxicity. Here, we analyzed two new compounds, 4-chlorochablastine and 4-chlorochacristine, with regard to their biological activity...
April 30, 2018: Current Cancer Drug Targets
Yuan Seng Wu, Zhong Yang Lee, Lay-Hong Chuah, Chun Wai Mai, Siew Ching Ngai
Despite advances in the treatment regimen, the high incidence rate of breast cancer (BC) deaths is mostly caused by metastasis. Recently, the aberrant epigenetic modifications, which involve DNA methylation, histone modifications and microRNA (miRNA) regulations become attractive targets to treat metastatic breast cancer (MBC). In this review, the epigenetic alterations of DNA methylation, histone modifications and miRNA regulations in regulating MBC is discussed. The preclinical and clinical trials of epigenetic drugs such as the inhibitor of DNA methyltransferase (DNMTi) and the inhibitor of histone deacetylase (HDACi), as a single or combined regimen with other epigenetic drug or standard chemotherapy drug to treat MBCs are discussed...
April 30, 2018: Current Cancer Drug Targets
Oliesia Gonzales Quinones, Maria Bernadete Riemma Pierre
BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) and particularly selective cyclooxygenase-2 (COX-2) inhibitors such as celecoxib (Cxb) are considered promising cancer chemopreventive for colon, breast, prostate, lung, and skin cancers. However, the clinical application to the prevention is limited by concerns about safety, potential to serious toxicity (mainly for healthy individuals), efficacy and optimal treatment regimen. Cxb exhibits advantages as potent anti-inflammatory and gastrointestinal tolerance compared with conventional NSAID's...
April 30, 2018: Current Cancer Drug Targets
Bing-Di Yan, Xiao-Feng Cong, Sha-Sha Zhao, Meng Ren, Zi-Ling Liu, Zhi Li, Chen Chen, Lei Yang
BACKGROUND AND OBJECTIVE: We performed this systematic review and meta-analysis to assess the efficacy and safety of antigen-specific immunotherapy (Belagenpumatucel-L, MAGE-A3, L-BLP25, and TG4010) in the treatment of patients with non-small-cell lung cancer (NSCLC). METHOD: A comprehensive literature search on PubMed, Embase, and Web of Science were conducted. Eligible studies were clinical trials of patients with NSCLC who received the antigen-specific immunotherapy...
April 30, 2018: Current Cancer Drug Targets
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"